At this time, patents prevent a generic Dulera (mometasone/formoterol) product from being manufactured. The earliest predictable date that a generic version of the drug could become available is January 2014, when the first patent expires. However, lawsuits or other patents for specific uses of Dulera may delay the manufacturing of a generic version of the drug.
Dulera® (mometasone/formoterol) is a prescription medication used for asthma treatment. It is used to control asthma or prevent asthma symptoms. It is not used to treat an asthma attack.
Dulera is a combination of two asthma medications:
- Mometasone (Asmanex®) -- an inhaled corticosteroid
- Formoterol fumarate (Foradil®) -- a beta-adrenergic agonist.
Dulera is made by 3M Health Care, Ltd., for Schering Corporation. It is protected by patents that prevent a generic version from being manufactured.
The first patent for Dulera expires in January 2014. This is the earliest predictable date that a generic version could become available.
However, there are other circumstances that could come up to extend or shorten this exclusivity period. This could include such things as lawsuits or other patents for specific Dulera uses. Once the drug goes off-patent, there may be several companies that manufacture a generic Dulera drug.
No -- mometasone and formoterol are the active ingredients in Dulera, but they are not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off-patent, and another company besides the original manufacturer must make the product.